Sign In
Buy GLP
$48.45
-0.81 (-1.64%)
At Close: Jun 03, 2026
Eli Lilly Just Opened the Door to Even Greater GLP-1 Growth
11:19am, Monday, 16'th Mar 2026
Eli Lilly 's ( NYSE:LLY ) GLP-1 therapy Zepbound has become the biggest weight loss drug since its introduction, outpacing Novo Nordisk 's ( NYSE:NVO ) Wegovy in both sales momentum and patient prefer
3 Companies at the Forefront of the GLP-1 Pill Wars
07:44am, Monday, 16'th Mar 2026
Though the first GLP-1 agonists date back more than 20 years, it's only in the last couple of years that they began to dominate the pharmaceutical space for their massive potential as weight loss dru
Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ACCESS II, demonstrating highest efficacy among oral G
Eli Lilly's Employer Push Could Unlock New GLP-1 Demand
08:19am, Sunday, 15'th Mar 2026
The world's most valuable pharmaceutical stock, Eli Lilly and Company NYSE: LLY, has continued to assert its dominance in the weight-loss and diabetes drug market in 2026.
Will Policy Shifts Accelerate Demand for Eli Lilly's GLP-1 Drugs?
01:51pm, Thursday, 12'th Mar 2026
LLY is likely to see stronger demand for its GLP-1 drugs as Medicare expands coverage and the company prepares to launch an oral obesity treatment.
Can Novo Nordisk's Hims & Hers Deal Revive Its GLP-1 Momentum?
10:25am, Wednesday, 11'th Mar 2026
NVO partners with HIMS to expand access to Ozempic and Wegovy via telehealth, aiming to shift patients from compounded GLP-1s to FDA-approved drugs.
Revisiting The Preferred Stock Of Global Partners
08:30am, Wednesday, 11'th Mar 2026
Global Partners (GLP.PR.B) preferred stock offers a 9.3% yield with a wide margin of safety despite recent geopolitical turmoil. GLP's resilient business model, demonstrated during past oil price shoc
Hims & Hers Health: The GLP-1 Chaos Is Fading, The Thesis Is Still On Track
04:43pm, Tuesday, 10'th Mar 2026
Hims & Hers Health, Inc. surges after securing a partnership with Novo Nordisk, resolving legal and regulatory overhangs tied to compounded GLP-1s. HIMS's long-term platform thesis centers on becoming
GLP-1 weight-loss drug race heats up as new rival matches Wegovy results with fewer side effects
12:48pm, Tuesday, 10'th Mar 2026
Citi stays 'neutral' on Novo Nordisk as crowded obesity market threatens to erode its competitive edge Novo Nordisk (NYSE:NVO), the Danish pharma giant behind the Ozempic and Wegovy weight-loss drugs,
FDA Warns Novo Nordisk of Unreported Side Effects Tied to GLP-1 Patients
12:33pm, Tuesday, 10'th Mar 2026
The FDA underscored cases including two deaths and a suicide linked to patients taking semaglutide, which Novo markets as Ozempic and Wegovy.
Should Value Investors Buy Global Partners (GLP) Stock?
10:40am, Tuesday, 10'th Mar 2026
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
NorthStrive Biosciences Announces Launch of EL-32 Preclinical Study Evaluating Muscle Preservation in GLP-1 Weight Loss Therapy
07:30am, Tuesday, 10'th Mar 2026
NEWPORT BEACH, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) (“PMGC” or the “Company”) today announced the initiation of a preclinical study for EL-32, an engine
- ASC30 subcutaneous (SQ) depot formulation achieved statistically significant and clinically meaningful placebo-adjusted mean weight loss of 7.5% at week 16 after three monthly doses. - ASC
Lindt says GLP-1 users are eating more chocolate, not less
04:11am, Tuesday, 10'th Mar 2026
Chocolate sales are rising faster among U.S. users of GLP-1 weight-loss drugs than in the rest of the population, Swiss chocolatier Lindt & Spruengli said on Tuesday, citing data that went again
Hims & Hers: Not Selling Yet
05:51pm, Monday, 09'th Mar 2026
Hims & Hers shares surged over 40% after renewing its partnership with Novo Nordisk to sell GLP-1 weight-loss drugs. The new deal reverses last year's public fallout, restoring a key catalyst for Hims
